1Jensen C, Herold P, Brunner HR. Aliskiren: the first renin inhibitor for clinical treatment [J]. Nat Rev,2008,7(5) : 399 -410.
2Wood JM. Structure - based design of aliskiren, a novel orally effective renin inhibitor. Biochem [J]. Biophys Res Commun, 2003,308(4) : 698 -705.
3Buczko W, Hermanowicz JM. Pharmacokinetics and pharmacodynamics of aliskiren, an oral direct renin inhibitor [ J]. Pharmacol Rep,2008,60(5) : 623 -631.
4Vaidyanathan S, Valencia J, Kemp C, et al. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide ( HCTZ ) and ramipril in healthy volunteers [J]. Int J Clin Pract,2006,60(11) : 1343 -1356.
5Vaidyanathan S,Camenisch G, Schuetz H, et al. Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P- Glycoprotein in the disposition of aliskiren [J]. J Clin Pharmacol, 2008,48 ( 11 ) : 1323 - 1338.
6Stanton A, Jensen C, Nussberger J, et al. Blood pressure lowering in essential hypertension with an oral rennin inhibitor, aliskiren [J]. Hypertension,2003,42(6) : 1137 - 1143.
8Oh BH, Mitchell J, Herron JR, et al. Aliskiren, an oral renin inhibitor, provides dose - dependent efficacy and sustained 24 - hour blood pressure control in patients with hypertension [ J ]. J Am Coll Cardiol,2007,49( 11 ) : 1157 - 1163.
9Azizi M. Direct renin inhibition: clinical pharmacology [ J ]. J Mol Med,2008,86(6) : 647 -654.
10Dietz R, Dechend R,Yu CM, et al. Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension [ J ]. J Renin Angiotensin Aldosterone Syst, 2008,9(3): 163 -175.
3de Silva L, Weir MR. Renin inhibition and microa1buminuria development: meaningful predictor of kidney disease progression[J]. Curr Opin Nephrol Hypertens, 2010, 19(5): 437-443.
4Campbell DJ, Woodward M, Chalmers JP, et al. Prediction of myocardial infarction by N-terminal-pro-B-type natriuretic peptide, C-reactive protein, and renin in subjects with cerebrovascular disease[J]. Circulation, 2005, 112(1): 110- 116.
5Azizi M, Webb R, Nussberger J, et al. Renin inhibition with aliskiren: where are we now, and where are we going?[J]. J Hypertens, 2006, 24(2): 243-256.
6Angeli F, Reboldi G, Mazzotta G, et al. Safety and efficacy of aliskiren in the treatment of hypertension and associated clinical conditions[J]. Curr Drug Saf, 2012, 7(1): 76-85.
7Musini VM, Fortin PM, Bassett K, et al. Blood pressure lowering efficacy of renin inhibitors for primary hypertension: a Cochrane systematic review[J]. J Hum Hypertens, 2009, 23(8): 495-502.
8Oh BH, Mitchell J, Herron JR, et al. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24- hour blood pressure control in patients with hypertension[J]. J Am Coli Cardiol, 2007, 49(11): 1157-1163.
9Verdecchia P, Angeli F, Mazzotta G, et al. Aliskiren versus ramipril in hypertension[J]. Ther Adv Cardiovasc Dis, 2010, 4(3): 193-200.
10Duggan ST, Chwieduk CM, Curran MP. Aliskiren: a review of its use as monotherapy and as combination therapy in the management of hypertension[J]. Drugs, 2010, 70(15): 2011- 2049.
